Speed of onset.
Speed of onset can be an important attribute of drug product performance. In studies employing appropriate designs and outcome measures, it is theoretically possible to make internally valid comparisons of the distribution of onset times associated with the use of two or more drug products. The external validity of such estimates is still potentially arguable. Steps that may be taken to enhance the likelihood that the results of such comparative studies will be accepted as valid bases for comparative claims are discussed.